{
    "clinical_study": {
        "@rank": "4851", 
        "acronym": "RESTORE", 
        "arm_group": [
            {
                "arm_group_label": "Experimental Arm 1", 
                "arm_group_type": "Experimental", 
                "description": "ONO-2952 Active tablets, every day for 2 weeks"
            }, 
            {
                "arm_group_label": "Placebo Arm", 
                "arm_group_type": "Placebo Comparator", 
                "description": "ONO-2952 Matching Placebo every day for 2 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "The objective is to evaluate whether ONO-2952 modulates visceral pain perception produced by\n      rectal distention in female patients with IBS-D"
        }, 
        "brief_title": "Study to Evaluate the Effects of ONO-2952 on Pain Perception Produced by Rectal Distention in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)", 
        "condition": "Irritable Bowel Syndrome (IBS)", 
        "condition_browse": {
            "mesh_term": "Irritable Bowel Syndrome"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Female 18-65 years of age (inclusive)\n\n          2. Diagnosed with IBS based on the following criteria (Rome III criteria):\n\n               -  Symptom onset at least 6 months prior to diagnosis, and\n\n               -  Recurrent abdominal pain or discomfort at least 3 days per month for the past 3\n                  months, and\n\n               -  Abdominal discomfort or pain associated with two or more of the following at\n                  least 25% of the time:\n\n               -  improvement with defecation\n\n               -  onset associated with a change in frequency of stool/defecation\n\n               -  onset associated with a change in form (appearance) of stool\n\n          3. Diagnosed with IBS-D, defined as loose/watery stools \u2265 25% and hard/lumpy stools \u2264\n             25% of defecations\n\n        Exclusion Criteria:\n\n          -  Any structural abnormality of the gastrointestinal (GI) tract (other than esophagitis\n             or gastritis)\n\n          -  History of Chron's disease, ulcerative colitis, diabetes mellitus, lactose\n             malabsorption, malabsorption syndromes, celiac sprue, or any upper GI symptoms that\n             may impact the assessment of IBS symptoms"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01887002", 
            "org_study_id": "ONO-2952POU005"
        }, 
        "intervention": [
            {
                "arm_group_label": "Experimental Arm 1", 
                "description": "ONO-2952 Active tablets, every day for 2 weeks", 
                "intervention_name": "ONO-2952", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo Arm", 
                "description": "ONO-2952 Matching Placebo every day for 4 weeks", 
                "intervention_name": "Placebo comparator", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Irritable Bowel Syndrome", 
            "IBS", 
            "ONO-2952"
        ], 
        "lastchanged_date": "April 16, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02215"
                    }, 
                    "name": "Boston Clinical Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Louis", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63110"
                    }, 
                    "name": "St. Louis Clinical Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chapel Hill", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27599"
                    }, 
                    "name": "Chapel Hill Clinical Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oklahoma", 
                        "country": "United States", 
                        "state": "Oklahoma", 
                        "zip": "73160"
                    }, 
                    "name": "Oklahoma City Clinical Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 2, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Effects of ONO-2952 on Pain Perception Produced by Rectal Distention in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) (RESTORE)", 
        "overall_contact": {
            "email": "s-patel@ono-uk.co.uk", 
            "last_name": "Sheetal Patel"
        }, 
        "overall_official": {
            "affiliation": "Ono Pharmaceutical Co. Ltd", 
            "last_name": "Ono Pharma USA, Inc.", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change in pain intensity rating during rectal distention by using a numeric pain rating scale", 
            "safety_issue": "No", 
            "time_frame": "2 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01887002"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Safety assessed through adverse events and clinical laboratory values", 
            "safety_issue": "Yes", 
            "time_frame": "2 weeks"
        }, 
        "source": "Ono Pharmaceutical Co. Ltd", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ono Pharma USA Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}